Metastatic index of non-small-cell lung cancer and long-term survival

Abstract

Aim

We aimed to determine whether metastatic index is a factor determining long-term survival in patients undergoing curative resection for non-small-cell lung cancer.

Methods

There were 2695 consecutive pulmonary resections performed between October 2001 and September 2011 in our institution; 1795 were potentially curative resections for non-small-cell lung cancer with bronchial margin length data available. Benchmarking against the International Association for the Study of Lung Cancer data set was performed. Cox multivariate analysis was undertaken. Metastatic index was defined as N stage× bronchial resection margin length.

Results

Benchmarking failed to reveal any significant differences between our data and the International Association for the Study of Lung Cancer data set. Univariate analysis identified metastatic index as a significant factor determining long-term survival (p = 0.04). Cox regression demonstrated that metastatic index (hazard ratio 1.29, p = 0.0002), age (hazard ratio 1.02, p < 0.0001), body mass index (hazard ratio 0.98, p = 0.006), female sex (hazard ratio 0.65, p < 0.0001), T1 stage (hazard ratio 0.67, p < 0.0001), T2 stage (hazard ratio 2.13, p < 0.0001), T3 stage (hazard ratio 1.59, p = 0.03), forced expiratory volume in 1 s (hazard ratio 0.70, p < 0.0001), pneumonectomy (hazard ratio 1.43, p = 0.001), histology subtype adenosquamous (hazard ratio 3.77, p = 0.01) and squamous (hazard ratio 0.83, p = 0.03) were all significant determinants of long-term survival.

Conclusion

Metastatic index is a significant factor determining long-term survival in patents with adenocarcinoma undergoing potentially curative surgery with a lobectomy.

Keywords

Bronchi carcinoma non-small-cell lung lung neoplasms neoplasm staging prognosis

Get full access to this article

View all access options for this article.

References

Irwin

Greer

Khatib

Temel

Pirl

. Early palliative care and metastatic non-small cell lung cancer: potential mechanisms of prolonged survival. Chron Respir Dis 2013; 10: 35–47.

Rosell

Bivona

Karachaliou

. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 2013; 382: 720–731.

Choe

Shin

Kim

. Tumor-stromal interactions with direct cell contacts enhance motility of non-small cell lung cancer cells through the hedgehog signaling pathway. Anticancer Res 2013; 33: 3715–3723.

Wang

Zhou

. TLR9 signaling repressed tumor suppressor miR-7 expression through up-regulation of HuR in human lung cancer cells. Cancer Cell Int 2013; 13: 90–90.

Tsuchida R, Osawa T, Wang F, et al. BMP4/Thrombospondin-1 loop paracrinically inhibits tumor angiogenesis and suppresses the growth of solid tumors. Oncogene 2013 Sep 9. doi: 10.1038/onc.2013.358. [Epub ahead of print].

Rusch

Asamura

Watanabe

Giroux

Rami-Porta

Goldstraw

. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2009; 4: 568–577.

Warwick

Shackcloth

Mediratta

. Female sex and long-term survival post curative resection for non-small-cell lung cancer. Eur J Cardiothorac Surg 2013; 44: 624–630.

Poullis

McShane

Shaw

. Prediction of in-hospital mortality following pulmonary resections: improving on current risk models. Eur J Cardiothorac Surg 2013; 44: 238–242.

Sheel

McShane

Poullis

. Survival of patients with or without symptoms undergoing potentially curative resections for primary lung cancer. Ann Thorac Surg 2013; 95: 276–284.

10.

Poullis

McShane

Shaw

. Smoking status at diagnosis and histology type as determinants of long-term outcomes of lung cancer patients. Eur J Cardiothorac Surg 2013; 43: 919–924.

11.

Yang

Shih

. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 2012; 13: 539–548.

12.

Zhou

Chen

. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735–742.

13.

Poullis

McShane

Shaw

. Bronchial resection margin and long-term survival in non-small-cell lung cancer. Asian Cardiovasc Thorac Ann 2012; 20: 432–448.

14.

Tomaszek

Kim

Cassivi

. Bronchial resection margin length and clinical outcome in non-small cell lung cancer. Eur J Cardiothorac Surg 2011; 40: 1151–1156.

15.

Fontaine

McShane

Carr

. Does positron emission tomography scanning improve survival in patients undergoing potentially curative lung resections for non-small-cell lung cancer? Eur J Cardiothorac Surg 2011; 40: 642–646.

16.

Mordant

Grand

Cazes

. Adenosquamous carcinoma of the lung: surgical management, pathologic characteristics, and prognostic implications. Ann Thorac Surg 2013; 95: 1189–1195.

17.

Feld

Rubinstein

Weisenberger

. Sites of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies. J Clin Oncol 1984; 2: 1352–1358.

18.

Cangemi

Volpino

D’Andrea

. Local and/or distant recurrences in T1-2/N0-1 non-small cell lung cancer. Eur J Cardiothorac Surg 1995; 9: 473–478.